Getting down to cancer basics

March 30, 2009

Cancer mutations in the heart of gene regulation

Researchers have identified a new cancer gene - one that is common to many cancers and affects the most basic regulation of our genes. The new example - a gene on the X chromosome called UTX - is found in 10% of cases of multiple myeloma and 8% of esophageal cancers.

UTX plays a role in overall regulation of the activity of many genes and it is possible that other genes with similar roles will also be found to be involved in different tumor types. This is the first example of mutations in a gene of this functional class. The finding arose from a study of mutations in 4000 genes in kidney cancer.

"UTX is an important component of the transcriptional control machinery - it influences some of the most fundamental mechanisms controlling gene activity in our cells," explains Dr Andy Futreal, co-leader of the Cancer Genome Project at the Wellcome Trust Sanger Institute. "Unlike many cancer genes, UTX does not appear to be directly involved in cell division or cell death but in basic gene regulation and shows the depths to which cancers will plumb in order to get themselves ready to go."

The normal UTX protein modifies part of the structure holding DNA together in our cells. The composite DNA-protein structure, called chromatin, is not simply a scaffold, but plays an active role in controlling gene activity. The UTX protein alters a key organising subunit component of chromatin, called a histone. The protein is likely to be involved in both turning genes on and off, making it a key regulator of the yin-yang of gene control.

In the massive DNA sequencing study, the team found rare mutations of the UTX gene in clear cell renal cancer - a type of kidney cancer. When they expanded the search they found mutations in many cancer types - including one in ten multiple myeloma and one in twelve esophageal cancer cases.

"This work shows that mutations in genes with different functions can be found in human cancer through systematic approaches. These results indicate that cancer genes are not restricted to 'classical' roles of survival and cell proliferation, but can affect a variety of other cellular mechanisms," explains Professor Victor Velculescu, Associate Professor of Oncology and Director of Cancer Genetics from the Ludwig Center at Johns Hopkins and co-Director of Cancer Biology, at Johns Hopkins Kimmel Cancer Center. "UTX wouldn't have been found without this high-throughput type of study and indicates the type of novel findings we might expect from the International Cancer Genome Consortium."

The International Cancer Genome Consortium (ICGC) seeks to catalogue genetic abnormalities in 50 different tumour types. The possibility of uncovering new regulatory genes - like UTX - along with continued efforts to catalog cancer genes, will boost researchers' attempts to comprehensively describe different cancers which will to lead to expanding opportunities to reduce the global cancer burden.

The team showed that the biology of the mutation fitted their prediction. Cells that lacked a functional UTX gene showed notable slowing of growth when a copy of normal UTX was reintroduced. As well, substantial changes in gene transcription were noted. Genes with the most significant changes in expression were highly enriched in those most susceptible to control by UTX mediated histone modification.

The work identifies a new class of cancer genes that researchers can now pursue. These are genes that occupy the central control position of gene activity and act to keep cells from turning cancerous. When such 'tumor suppressor genes' are inactivated, other genes can run riot.

The consequence of mutation in UTX is to bring about changes in activity of other genes through epigenetic changes - their activity is changed by modification, not of their DNA code, but of their associated proteins and chemical tags.

"This is a genetic change with consequences at the level of epigenetic regulation," explains Professor Mike Stratton, co-leader of the Cancer Genome Project at the Sanger Institute. "When we look at cancers, a substantial proportion of the epigenetic disregulation may well have a genetic basis."

Wellcome Trust Sanger Institute

100 Questions and Answers About Myeloma (100 Questions & Answers about . . .)
by Asad Bashey (Author), Rafat Abonour (Author), James W. Huston (Author)

Whether you are a newly diagnosed myeloma patient, a survivor, or a friend or relative of either, this book offers help. The only text to provide the doctor s and patient s views, 100 Questions & Answers About Myeloma gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. Written by a hematologist-oncologist specializing in myeloma treatment, and featuring insider advice from an actual patient, this book is an invaluable resource for anyone coping with the physical and emotional turmoil of this frightening disease.

Multiple Myeloma: The Plain English Handbook for Patients and Care Givers
by Robert J Heller (Author)

A comprehensive handbook and guide in easy to understand terms dealing with Multiple Myeloma; the disease, treatments, medications, lifestyle changes, and resources. Written by a non-medical author and based upon personal experiences. Updated annually.

Medifocus Guidebook on: Multiple Myeloma
by Inc. Medifocus.com (Author), Elliot Jacob PhD. (Editor)

The MediFocus Guidebook on Multiple Myeloma is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Multiple Myeloma, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Multiple Myeloma, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts, institutions, and support...

My Bout with Multiple Myeloma
by Dennis Dinger (Author)

In 2008, the author was diagnosed with Multiple Myeloma, which is a blood plasma cancer. This book chronicles the author's battle - to include the times prior to diagnosis, the diagnosis itself, the treatments (four cycles of chemotherapy followed by one high dose cycle and an autologous stem cell transplant), and the recuperation period following all treatments. Since 2009, the cancer has been in complete remission. In this book, the author includes descriptions of most of the procedures to which he was subject, and he gives helpful hints and suggestions to others who may have to deal with this or other cancers. The book was written for those who have been similarly diagnosed, as well as for their family members and friends who may be called upon to support their loved ones through...

What You Need To Know About: Multiple Myeloma

This booklet is about multiple myeloma, a cancer that starts in plasma cells, a type of white blood cell. It's also called plasma cell myeloma. Each year in the United States, about 20,000 people learn they have this disease.

This booklet tells about diagnosis, treatment options, and tests the doctor may give you during follow-up visits. It also tells about supportive care before, during, or after treatment. Learning about the medical care for multiple myeloma can help you take an active part in making choices about your care.

Multiple Myeloma (Emerging Cancer Therapeutics) (Emerging Concepts Therapeutics) (Emerging Cancer Therapeutics V1 I2)
by Shaji Kumar MD (Editor), Jame Abraham MD FACP (Editor)

The second issue of Emerging Cancer Therapeutics focuses on multiple myelomas also known as plasma cell myeloma, Kahler's Disease and myelomatosis. It is estimated that over 20,000 new cases are diagnosed each year with over 10,000 people dying from these malignancies. Multiple myelomas are highly treatable but rarely curable. Thus it is crucial for the practitioner to be up-to-date on the latest insights regarding their management. Management options and outcomes for individuals with multiple myelomas improved dramatically with the introduction of chemotherapy. Even further improvements in prognosis have occurred because of the introduction of newer therapies such as pulse corticosteroids, thalidomide, bortezomib, and autologous and allogeneic stem cell transplantation. With the...

Multiple Myeloma Handbook: For Patients, Families and Friends
by Kenneth Westrate MD (Author), Susan Westrate (Editor)

The Multiple Myeloma Handbook offers an easy to understand explaination of the disease and its diagnosis, treatment, and prognosis. An additional section covers the classification systems used to discribe the stages of multiple myeloma. There is also a section on complications of the disease and their treatment. The reader will also find a list of resources for multiple myeloma patients, and and a list of nationally recognized treatment centers. Extensive glosseries for medical terms and medications are very helpful for those without a medical background.

Multiple Myeloma (Recent Results in Cancer Research)
by Thomas Moehler (Editor), Hartmut Goldschmidt (Editor)

Multiple myeloma is currently still an incurable disease, but during the past decade knowledge of its molecular pathogenesis has increased rapidly. This has led to remarkable progress in both diagnosis and therapy, including in particular the approval of novel and first-in-class drugs such as thalidomide, bortezomib, and lenalidomide. This book, written by internationally acknowledged experts, covers a wide range of topics relating to multiple myeloma, including history, epidemiology, pathophysiology, clinical features, staging, and prognostic systems. The principal focus, however, is on therapy, with detailed information on the various promising treatment options which give hope that this cancer will be transformed into a chronic disease or even become curable. Individualized therapy and...

Living Proof: A Medical Mutiny
by Michael Gearin-Tosh (Author)

'I was told I had cancer and that I must expect to die soon. Almost eight years later I still do my job and enjoy life. I have not had conventional treatment. Did my cancer simply disappear? Did I do nothing? Far from it. A number of things happened, some by accident, most by design.' Michael Gearin-Tosh was diagnosed with cancer when he was fifty-four. Consultants urged immediate treatment. Michael refused. Living Proof is a story of how a man learns to steer, in his own way, between the medicine he rejects and the doctors he honours.

Living with Multiple Myeloma
by Pat Killingsworth (Author)